NICE recommends cannabis based drugs for epilepsy and multiple sclerosis

Source: BMJ News - Category: General Medicine Source Type: research

Related Links:

What are the current trends and hot topics in neurology? The increasing insights into the genetics and molecular bases of neurological disorders open new perspectives for specific and personalized treatments. This is evidenced most dramatically by the antisense therapy for spinal muscular atrophy. Promising neurological research currently targets neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Duchenne muscular atrophy, or Huntington’s disease. Likewise, brain-machine interfaces and neuroprosthetics offer huge potential. Never before has it been more important and more exc...
Source: BioMed Central Blog - Category: General Medicine Authors: Tags: Uncategorized Source Type: blogs
Publication date: Available online 20 November 2019Source: Neuroscience LettersAuthor(s): Sathiya Sekar, Changiz TaghibiglouAbstractGlyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been well documented in glycolytic pathway. Independent of this, it has various other functions including stimulator of programmed cell death. Reports suggest that glutamate receptor AMPA type-2 subunit (GluA2) forms protein complex with GAPDH and internalized during excitotoxicity. Further, nuclear accumulation of GluA2 and GAPDH have been studied in neurological disorders like epilepsy and multiple sclerosis, and disruption of this complex...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
CONCLUSIONS: In this review, biological and chemical knowledge of melatonin, its experimental effects, and the clinical impact on patients with neurological disorders were described. According to all of the beneficial results obtained from experimental and clinical trials, melatonin may have a prophylactic and therapeutic effect on neurological diseases. Strong collaboration between neurologists and health service policy makers is needed to encourage use of melatonin in the patients suffering from neurological diseases. Melatonin may be the solution we have been looking for. PMID: 31718830 [PubMed - as supplied by publisher]
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
The change comes after two highly publicized cases in which young epileptic patients depended on the treatments.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Cannabis Foods and Products Epilepsy Medical Marijuana Multiple Sclerosis Drugs (Pharmaceuticals) Chemotherapy England Wales Source Type: news
Children with two rare life-threatening forms of epilepsy will now have access to the drug Epidyolex, which helps to reduce seizures. Patients with MS will be offered a cannabis-based spray.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Politicians running scared of big pharma and the taboo around cannabis are blocking access to these vital drugsThat the government will allow a few serious epilepsy and multiple sclerosis sufferers to getcannabidiol medicine to relieve their symptoms is good news. That is all that can be said. Once more a decision emerges from the caverns of Britain ’s NHS that reveals the evils of a politicised, centralised, deadened health service.Related:Legalisation of cannabis in the UK would help protect its users from harm | James NichollsContinue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cannabis Drugs Society NHS Health Epilepsy UK news Science Pharmaceuticals industry Business David Nutt Source Type: news
The drugs, used to treat epilepsy and multiple sclerosis, are recommended for use by the NHS in England.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
ConclusionEpilepsy in MS is associated with increased mortality although death from epilepsy is rare. Most MS patients with epilepsy died of MS, and epilepsy was most lethal when developed in SPMS. We thus suggest that development of epilepsy is a marker of severe MS. Despite this, we found no association between epilepsy and conversion to SPMS.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Abstract Purinergic signaling was proposed in 1972, after it was demonstrated that adenosine 5'-triphosphate (ATP) was a transmitter in nonadrenergic, noncholinergic inhibitory nerves supplying the guinea-pig taenia coli. Later, ATP was identified as an excitatory cotransmitter in sympathetic and parasympathetic nerves, and it is now apparent that ATP acts as a cotransmitter in most, if not all, nerves in both the peripheral nervous system and central nervous system (CNS). ATP acts as a short-term signaling molecule in neurotransmission, neuromodulation, and neurosecretion. It also has potent, long-term (trophic) ...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
Inder Puri, Govind Singh, Rajendra Kumar Acharya, Divya GoswamiAnnals of Indian Academy of Neurology 2019 22(4):373-376 New disability law called “Rights of Persons with Disabilities Act 2016” has been acted in 2016. The United Nations' Convention for Rights of Persons with Disabilities is the sole of this new act. Of the total 21 categories, three new neurological legal disability categories such as chronic neurological conditions, Parkinson disease (PD), and multiple sclerosis have been notified first time in the new act. The new guidelines have been notified in the year 2018 for evaluation and certifica...
Source: Annals of Indian Academy of Neurology - Category: Neurology Authors: Source Type: research
More News: Epilepsy | General Medicine | Multiple Sclerosis | National Institute for Health and Clinical Excelle